Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918809 · ClinicalTrials.gov registry record
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings
A clinical trial of Diffuse Large B Cell Lymphoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,031
- Enrollment target
- 1
- Study location
NCT05918809: Completed study of Diffuse Large B Cell Lymphoma, sponsored by Novartis Pharmaceuticals.
NCT05918809 is a study of Diffuse Large B Cell Lymphoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,031 participants, above the 210-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (391% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05918809, a study of Diffuse Large B Cell Lymphoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,031 participants
- Enrollment target
- 1
- Study location
Study Summary
A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with chimeric antigen receptor modified T cell (CAR-T) therapy among patients with DLBCL.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,031 participants |
| Start Date | 2021-07-25 |
| Est. Completion | 2022-06-17 |
What the finished NCT05918809 record still lists
NCT05918809 is an observational study that tracks outcomes without assigning an intervention. Its 1,031 participants enrollment target places it among the larger protocols in the corpus, above the 210-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (391% higher).
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT05918809 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05918809 about?
NCT05918809 is a clinical study titled "Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings". A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with chimeric antigen receptor modified T cell (CAR-T) thera...
What is the current status of trial NCT05918809?
This trial is currently completed. The enrollment target is 1,031 participants. The study started on 2021-07-25. Estimated completion is 2022-06-17.
What conditions does trial NCT05918809 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
Who is sponsoring clinical trial NCT05918809?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918809 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05918809's enrollment target sits among peer trials
1,031 3rd of 114 higher than 112 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
RECRUITING
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07084363 · 1,032 participants · NA
Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery
- NCT06080698 · 1,030 participants · NA
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
- NCT05037682 · 1,035 participants · NA
Pain and Opioid Management in Older Adults
- NCT07282600 · 1,035 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI